SCHEMBL790403

SCHEMBL790403

Nc1cccc(C(F)(F)F)c1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.40
POLB P06746 3/20 0.39
ALDH1A1 P00352 3/20 0.39
TDP1 Q9NUW8 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TSHR P16473 5/20 0.37
GAA P10253 2/20 0.37
GLA P06280 1/20 0.37
MAPK1 P28482 1/20 0.37
IDO1 P14902 2/20 0.36
CYP3A4 P08684 4/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MPL P40238 2/20 0.36
CUL4A Q13619 1/20 0.36
KEAP1 Q14145 1/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
PNMT P11086 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5794355 0.85 TSHR (0.43) POLBALDH1A1TDP1L3MBTL1TSHR
SCHEMBL24126312 0.85 CA2 (0.41) HSD11B1POLBALDH1A1TDP1L3MBTL1
SCHEMBL8166836 0.85 TSHR (0.36) HSD11B1POLBALDH1A1TDP1L3MBTL1
SCHEMBL8174823 0.85 TSHR (0.33) HSD11B1POLBALDH1A1TDP1L3MBTL1
SCHEMBL25696408 0.85 CA2 (0.37) HSD11B1POLBALDH1A1TDP1L3MBTL1
SCHEMBL2000756 0.82 HSD11B1 (0.46) HSD11B1POLBALDH1A1TDP1L3MBTL1
SCHEMBL10700852 0.81 NOS3 (0.35) HSD11B1POLBALDH1A1TDP1L3MBTL1
SCHEMBL6319546 0.81 TSHR (0.31) POLBALDH1A1TDP1L3MBTL1TSHR
SCHEMBL16340864 0.80 HSD11B1 (0.44) HSD11B1POLBALDH1A1TDP1L3MBTL1
Lithium SCHEMBL5691154 0.79 HSD11B1 (0.44) HSD11B1POLBALDH1A1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2579870-B1 TRKB AGONISTS AND METHODS OF USE UNIV EMORY (US) 2018-02-14 EP claimed
EP-2579870-A2 TRKB AGONISTS AND METHODS OF USE Emory University (US) 2013-04-17 EP claimed
US-20130040947-A1 TRKB AGONISTS AND METHODS OF USE EMORY UNIVERSITY (US) 2013-02-14 US claimed
WO-2011156479-A9 TRKB AGONISTS AND METHODS OF USE EMORY UNIVERSITY (US) 2012-05-31 WO claimed
WO-2011156479-A2 TRKB AGONISTS AND METHODS OF USE EMORY UNIVERSITY (US) 2011-12-15 WO claimed
US-5075378-A Coating of an epoxy resin, fluorocarbon polymer fluorinated curing agent THE STANDARD OIL COMPANY (US) 1991-12-24 US claimed
US-5035970-A Encapsulated toner compositions and processes thereof XEROX CORPORATION (US) 1991-07-30 US claimed
CN-117043232-B Method for producing polyimide resin powder 三菱瓦斯化学株式会社 2024-10-22 CN disclosed
US-20240199810-A1 METHOD FOR PRODUCING POLYIMIDE RESIN POWDER MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-06-20 US disclosed
WO-2024028893-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2024-02-08 WO disclosed
EP-4317254-A1 METHOD FOR PRODUCING POLYIMIDE RESIN POWDER MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-02-07 EP disclosed
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. 2024-01-25 US disclosed
CN-117043232-A Method for producing polyimide resin powder 三菱瓦斯化学株式会社 2023-11-10 CN disclosed
EP-1517927-A1 CATALYST COMPOSITION FOR OLEFIN POLYMERIZATION DSM IP Assets B.V. (NL) 2005-03-30 EP disclosed
WO-2004003030-A1 CATALYST COMPOSITION FOR OLEFIN POLYMERIZATION DSM IP ASSETS B.V. (NL) 2004-01-08 WO disclosed
EP-0880555-B1 METHOD OF MAKING FREE-STANDING POLYIMIDE FILM OCCIDENTAL CHEM CO (US) 2000-03-08 EP disclosed
EP-0119428-A2 Biscarboxamides for treating diseases, and process for their preparation BAYER AG (DE) 1984-09-26 EP disclosed
EP-0001002-B1 INDANAMINES, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM SMITHKLINE BECKMAN CORPORATION (US) 1981-08-12 EP disclosed
EP-0001002-A1 Indanamines, processes for their preparation and compositions containing them SMITHKLINE BECKMAN CORPORATION (US) 1979-03-07 EP disclosed
US-4128666-A PHENYLETHANOLAMINE N-METHYL-TRANSFERASE INHIBITORS SMITHKLINE CORPORATION (US) 1978-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040947-A1 TRKB AGONISTS AND METHODS OF USE NTRK2, BDNF, NTRK1 HSD11B1 1700/4885POLB 3440/4885ALDH1A1 1116/4885
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF AZI2, TET3, OXA1L HSD11B1 782/4885POLB 1891/4885ALDH1A1 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.